EPAM Systems (EPAM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 revenues reached $1.168 billion, up 1.3% year-over-year, with strong execution, improved client engagement, and stabilizing demand across verticals and geographies.
Non-GAAP diluted EPS grew 14.3% year-over-year to $3.12; GAAP diluted EPS rose 43.6% to $2.37, driven by Poland R&D incentives.
Major acquisitions included NEORIS, expanding presence in Latin America, Spain, and the U.S., and a pending First Derivative deal.
Over 53,250 employees across 55+ countries, with a focus on AI-driven solutions, digital transformation, and strong partnerships with AWS, Google, and Microsoft.
Continued commitment to employee safety in Ukraine, with a $100 million humanitarian program and ongoing adaptation to geopolitical risks.
Financial highlights
Q3 revenue was $1.168 billion, up 1.3% year-over-year; 2023 full-year revenue was $4.691 billion.
GAAP gross margin improved to 34.6% (vs. 31.1% last year), aided by a $52 million Poland R&D incentive.
GAAP income from operations was $177 million (15.2% margin); non-GAAP income from operations $223 million (19.1% margin).
GAAP diluted EPS was $2.37; non-GAAP diluted EPS $3.12, both up significantly year-over-year.
Cash and equivalents at $2.041 billion as of September 30, 2024; free cash flow reached a record $237 million in Q3.
Outlook and guidance
Q4 2024 revenue expected at $1.205–$1.215 billion, up 4.6% year-over-year, including $54 million from NEORIS.
Full-year 2024 revenue expected at $4.685–$4.695 billion, flat year-over-year at midpoint.
Full-year GAAP diluted EPS expected at $7.78–$7.86; non-GAAP at $10.73–$10.81.
Production headcount expected to return to year-over-year growth in Q4 after seven quarters of decline.
Additional restructuring charges of $14 million expected under the 2024 Cost Optimization Program.
Latest events from EPAM Systems
- Accelerating as an AI-native leader, targeting 16%+ margins and $1.8B+ free cash flow by 2028.EPAM
Investor Day 202612 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q4 2024 delivered strong growth and 2025 guidance targets double-digit revenue gains.EPAM
Q4 202413 Dec 2025 - Board declassification, majority voting, and new incentive plan headline 2025 proxy.EPAM
Proxy Filing1 Dec 2025 - Proxy seeks approval for board declassification, majority voting, and new long-term incentive plan.EPAM
Proxy Filing1 Dec 2025 - Key votes include director elections, governance reforms, and executive pay approval.EPAM
Proxy Filing1 Dec 2025 - Leadership transition announced: Dobkin to Executive Chairman, Fejes to CEO in September 2025.EPAM
Proxy Filing1 Dec 2025 - Q2 revenue up 18% year-over-year; full-year outlook raised, margins pressured by higher costs.EPAM
Q2 202523 Nov 2025